

Drug Monograph

Drug Name: **Semglee® (insulin glargine) pens and vials**
 Drug Class: **Endocrine and Metabolic Agents: Insulins, Long-Acting**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Semglee is available in 100 units/mL prefilled pens and multiple-dose vials.

Manufacturer: Distributed by: Mylan Specialty L.P., Morgantown, WV 26505.

Indications: Semglee is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Costs: \$80.81 per pen and \$269.38 per vial of Semglee. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.

Status Recommendation:

<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
<input type="checkbox"/> Open Access	<input checked="" type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Non-Preferred
<input type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD
 Date: December 30, 2021